Avanos Medical Secures All Regulatory Approvals for $1.27B Acquisition by American Industrial Partners
AVNS has more than doubled off its 52-week low of $9.303 on light trading volume (0.2× avg).
Summary
Avanos Medical announced it has secured all required regulatory approvals for its pending acquisition by American Industrial Partners, bringing the $1.27 billion deal closer to its expected closing.
Key Events · M&A and Partnerships · AVNS
-
Regulatory Approvals Secured
Avanos Medical and American Industrial Partners have received all necessary regulatory approvals to complete the pending acquisition.
-
Merger Progress
This development is a significant step towards finalizing the acquisition, which was initially announced on April 14, 2026, for approximately $1.272 billion or $25.00 per share.
-
Shareholder Vote Pending
The transaction is now subject to Avanos stockholder approval at a special meeting scheduled for July 22, 2026, with an expected closing no later than July 27, 2026.
Analysis · AVNS · Industrial Applications And Services
This filing confirms that Avanos Medical has received all necessary regulatory approvals for its acquisition by American Industrial Partners. This is a critical milestone that significantly de-risks the transaction, moving it closer to completion. The final step is shareholder approval, which is scheduled for July 22, 2026, with an expected closing date no later than July 27, 2026.
At the time of this filing, AVNS was trading at $24.93 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $9.30 to $25.49. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.